Gyros Protein and Luxembourg Bio sign distribution agreement

Deal for peptide synthesis reagents includes exclusive distribution of PurePep coupling agents in North America

Register for free to listen to this article
Listen with Speechify
UPPSALA, Sweden—In late April, Gyros Protein Technologies AB, which calls itself “a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents,” announced it had signed an exclusive distribution agreement with Luxembourg Bio Technologies for two of its proprietary coupling agents, PyOxim and K-Oxyma, and HDMA on a non-exclusive basis. Gyros Protein Technologies will sell these reagents as part of its PurePep brand.
Under the terms of the agreement, Gyros Protein Technologies has the exclusive rights to promote and sell these PurePep products to researchers in North America, and globally on a non-exclusive basis. The addition of the PurePep Coupling Agents to Gyros Protein Technologies’ offering further enables researchers to efficiently synthesize simple to complex peptides, by increasing coupling efficiency and reducing racemization. 
“Gyros Protein Technologies takes pride in providing high quality peptide synthesis reagents and platforms. At the core of Gyros Protein Technologies’ PurePep product brand is purity, trust and ingenuity in peptide synthesis, supporting the company’s pure reliability solution strategy—synthesizers, software and reagents—which are in turn underpinned by our decades-long track record of providing customers with outstanding service and support,” said Jasmine Gruia-Gray, vice president of marketing for Gyros Protein Technologies. “We are pleased to partner with Luxembourg Bio Technologies, given their strong market position as a provider of high quality and innovative peptide synthesis reagents.”
Gyros Protein Technologies’ peptide synthesizer platforms are used in conjunction with PurePep reagents, which include bulk and pre-packed amino acids, resins, coupling agents and solvents. Peptide synthesis optimization using these reagents minimizes down time caused by clogging that can result from using impure and unstable reagents. The platforms ensure that peptides are synthesized correctly the first time, with consistent quality and reduced synthesis variability.
Yoav Luxembourg, CEO of Luxembourg Bio Technologies, said: “We are pleased to have Gyros Protein Technologies as our partner, and our distribution agreement represents an important step to enable more researchers to have access to the highest-quality coupling agents designed to provide maximum yield with minimal racemization.”
Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue